Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lily L Remsing

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of the American Chemical Society|February 21, 2002
Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathwayLily L Remsing, Jose Garcia-Bernardo, Ana Gonzalez, et al.
Cell Chemical Biology|October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Nature Chemical Biology|October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomicsBrent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Molecular Oncology|November 8, 2017
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibitionManali Phadke, Lily L Remsing Rix, Inna Smalley, et al.
Journal of the American Chemical Society|May 8, 2003
Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesisLily L Remsing, Ana M González, Mohammad Nur-e-Alam, et al.
Blood|August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsUwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
ACS Chemical Biology|May 31, 2017
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer ActivityGabriela Wright, Volha Golubeva, Lily L Remsing Rix, et al.
ACS Chemical Biology|November 13, 2013
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsLily L Remsing Rix, Brent M Kuenzi, Yunting Luo, et al.
Chemistry & Biology|May 5, 2004
Generation of new landomycins by combinatorial biosynthetic manipulation of the LndGT4 gene of the landomycin E cluster in S. globisporusBohdan Ostash, Uwe Rix, Lily L Remsing Rix, et al.
Molecular & Cellular Proteomics : MCP|September 16, 2018
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer CellsClaudia Ctortecka, Vinayak Palve, Brent M Kuenzi, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of the American Chemical Society|February 21, 2002
Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathwayLily L Remsing, Jose Garcia-Bernardo, Ana Gonzalez, et al.
Cell Chemical Biology|October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Nature Chemical Biology|October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomicsBrent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Molecular Oncology|November 8, 2017
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibitionManali Phadke, Lily L Remsing Rix, Inna Smalley, et al.
Journal of the American Chemical Society|May 8, 2003
Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesisLily L Remsing, Ana M González, Mohammad Nur-e-Alam, et al.
Blood|August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsUwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
ACS Chemical Biology|May 31, 2017
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer ActivityGabriela Wright, Volha Golubeva, Lily L Remsing Rix, et al.
ACS Chemical Biology|November 13, 2013
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsLily L Remsing Rix, Brent M Kuenzi, Yunting Luo, et al.
Chemistry & Biology|May 5, 2004
Generation of new landomycins by combinatorial biosynthetic manipulation of the LndGT4 gene of the landomycin E cluster in S. globisporusBohdan Ostash, Uwe Rix, Lily L Remsing Rix, et al.
Molecular & Cellular Proteomics : MCP|September 16, 2018
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer CellsClaudia Ctortecka, Vinayak Palve, Brent M Kuenzi, et al.
Pageof 3